ArticleBJC reports2024
ASSIGN score and cancer risk in the Scottish Heart Health Extended Cohort (SHHEC) study.
Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this work was to determine whether the ASSIGN cardiovascular disease (CVD) score, a 10-year CVD risk score used in primary care in Scotland, could additionally detect cancer risk.
methods18,107 participants were recruited to the Scottish Heart Health Extended Cohort (SHHEC) study between 1982 and 1995. Information on health and lifestyle were collected, along with blood and urine, and participants were followed up via record linkage to 2017. Cox proportional hazards were used to estimate HRs (95% CIs) for time to cancer diagnosis.
resultsA total of 5046 cases of cancer were reported during the follow up period. ASSIGN was significantly associated with a diagnosis of cancer, with a 2.3-3.4% increase in risk of cancer per 1-point increase of ASSIGN. The components of ASSIGN predominantly associated with the risk of cancer were age (HR 1.52; 95% CI 1.48-1.56, cholesterol level (HR 1.11; 95% CI 1.08-1.13), diabetes status (HR 1.24; 95% CI 1.01-1.53), and systolic blood pressure (HR 1.16; 95% CI 1.13-1.19).
conclusionASSIGN could be used not only to predict CVD, but also to predict cancer risk in patients. This needs to be validated in further cohorts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.